Integrated genomic characterization of endometrial carcinoma.

Signatures of mutational processes in human cancer. Nature (2013) 21.63

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93

Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96

Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61

Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26

Network-based stratification of tumor mutations. Nat Methods (2013) 3.12

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91

Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86

Individualized medicine from prewomb to tomb. Cell (2014) 2.76

Integrated genomic characterization of oesophageal carcinoma. Nature (2017) 2.76

Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50

The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun (2014) 2.48

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science (2014) 2.42

Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30

A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun (2014) 2.25

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature (2015) 2.04

Systems genetics approaches to understand complex traits. Nat Rev Genet (2013) 1.97

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94

SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88

Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. Arthritis Rheumatol (2015) 1.84

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell (2014) 1.84

Data integration in the era of omics: current and future challenges. BMC Syst Biol (2014) 1.82

Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet (2013) 1.80

Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer (2014) 1.80

Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol (2014) 1.71

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol (2015) 1.68

The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell (2013) 1.68

Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat Methods (2015) 1.67

Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer (2014) 1.67

Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet (2014) 1.63

Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62

The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell (2015) 1.61

The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) (2015) 1.59

Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics (2014) 1.59

RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet (2014) 1.57

Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell (2014) 1.51

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol (2015) 1.49

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2013) 1.46

Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science (2014) 1.45

From human genome to cancer genome: the first decade. Genome Res (2013) 1.42

NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol (2014) 1.40

A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One (2014) 1.40

The mutational landscape of phosphorylation signaling in cancer. Sci Rep (2013) 1.39

BRCAness revisited. Nat Rev Cancer (2016) 1.38

Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics (2014) 1.37

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37

TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. Cancer Res (2015) 1.36

Differential DNA mismatch repair underlies mutation rate variation across the human genome. Nature (2015) 1.34

Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv (2015) 1.33

Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med (2014) 1.31

Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun (2014) 1.31

Characterizing DNA methylation alterations from The Cancer Genome Atlas. J Clin Invest (2014) 1.27

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun (2014) 1.27

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res (2015) 1.27

Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biol (2014) 1.25

Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. Genome Res (2014) 1.23

Genome Modeling System: A Knowledge Management Platform for Genomics. PLoS Comput Biol (2015) 1.21

The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21

Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst (2014) 1.21

Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res (2014) 1.18

Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18

Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. J Natl Cancer Inst (2016) 1.18

MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics (2013) 1.17

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med (2017) 1.17

Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16

Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations. Genome Biol (2015) 1.14

Tight junction proteins: from barrier to tumorigenesis. Cancer Lett (2013) 1.14

Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst (2014) 1.14

Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer (2015) 1.12

CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep (2014) 1.11

Patterns and processes of somatic mutations in nine major cancers. BMC Med Genomics (2014) 1.08

Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights. Clin Cancer Res (2013) 1.07

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06

A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer (2016) 1.06

Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06

A common cancer-associated DNA polymerase ε mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res (2014) 1.05

Lean Big Data integration in systems biology and systems pharmacology. Trends Pharmacol Sci (2014) 1.05

The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proc Natl Acad Sci U S A (2016) 1.04

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst (2014) 1.03

A TrkB-STAT3-miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells. Mol Cancer (2013) 1.03

Pan-cancer patterns of DNA methylation. Genome Med (2014) 1.02

Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev (2014) 1.02

Critical limitations of consensus clustering in class discovery. Sci Rep (2014) 1.02

The 'dnet' approach promotes emerging research on cancer patient survival. Genome Med (2014) 1.01

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet (2016) 1.01

The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep (2015) 1.01

Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol (2014) 1.01

Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun (2014) 1.00

Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00

TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics. Chin J Cancer (2014) 0.99

Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene (2014) 0.99

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46

CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02

Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25

Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09

Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78

Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21

Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics (2008) 3.89

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57

A flexible R package for nonnegative matrix factorization. BMC Bioinformatics (2010) 3.28

Regulation of Wnt signaling by Sox proteins: XSox17 alpha/beta and XSox3 physically interact with beta-catenin. Mol Cell (1999) 3.15

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A (2009) 2.72

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71

Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol (2007) 2.67

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 2.32

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91

Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87

PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res (1998) 1.77

Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol (2012) 1.72

A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol (1997) 1.61

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol (2005) 1.45

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One (2012) 1.45

Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. Gastroenterology (2005) 1.43

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res (2012) 1.39

Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol (2013) 1.36

Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol (2009) 1.34

Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol (2010) 1.23

Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol (2011) 1.14

Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

Whole-genome sequencing and variant discovery in C. elegans. Nat Methods (2008) 31.92

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44

BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41

The Genome sequence of the SARS-associated coronavirus. Science (2003) 16.68

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38

Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90

A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88

Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16

Extending assembly of short DNA sequences to handle error. Bioinformatics (2007) 14.46

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33

DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68

CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63

Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60

The genome sequence of Caenorhabditis briggsae: a platform for comparative genomics. PLoS Biol (2003) 13.32

Mapping copy number variation by population-scale genome sequencing. Nature (2011) 12.55

Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79

De novo gene disruptions in children on the autistic spectrum. Neuron (2012) 9.69

The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66

Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62

Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13

Complete Khoisan and Bantu genomes from southern Africa. Nature (2010) 9.06

The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01

A high-resolution map of human evolutionary constraint using 29 mammals. Nature (2011) 8.67

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76

Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61

Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56

HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 7.34

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09

Analyses of deep mammalian sequence alignments and constraint predictions for 1% of the human genome. Genome Res (2007) 7.05

Probabilistic Boolean Networks: a rule-based uncertainty model for gene regulatory networks. Bioinformatics (2002) 6.90

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81

Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80

Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71

Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res (2005) 6.49

Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48